PDT Partners’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.75M | Sell |
58,957
-89,764
| -60% | -$2.68M | 0.1% | 262 |
|
|
2025
Q4 | $5.68M | Sell |
148,721
-132,737
| -47% | -$4.32M | 0.37% | 74 |
|
|
2025
Q3 | $6.73M | Sell |
281,458
-68,119
| -19% | -$1.28M | 0.42% | 58 |
|
|
2025
Q2 | $5.17M | Buy |
349,577
+40,043
| +13% | +$664K | 0.29% | 100 |
|
|
2025
Q1 | $5.55M | Buy |
309,534
+62,425
| +25% | +$1.27M | 0.39% | 55 |
|
|
2024
Q4 | $4.3M | Sell |
247,109
-17,164
| -6% | -$304K | 0.38% | 64 |
|
|
2024
Q3 | $3.7M | Buy |
264,273
+25,490
| +11% | +$266K | 0.33% | 70 |
|
|
2024
Q2 | $1.96M | Buy |
238,783
+43,242
| +22% | +$291K | 0.19% | 205 |
|
|
2024
Q1 | $1.51M | Buy |
195,541
+134,020
| +218% | +$1.13M | 0.14% | 249 |
|
|
2023
Q4 | $553K | Buy |
+61,521
| New | +$448K | 0.06% | 393 |
|
|
2023
Q3 | – | Sell |
-23,845
| Closed | -$366K | – | 685 |
|
|
2023
Q2 | $366K | Sell |
23,845
-23,850
| -50% | -$434K | 0.05% | 426 |
|
|
2023
Q1 | $1.07M | Buy |
+47,695
| New | +$1.01M | 0.15% | 242 |
|
|
2022
Q3 | – | Sell |
-96,905
| Closed | -$2.35M | – | 1092 |
|
|
2022
Q2 | $2.35M | Sell |
96,905
-12,578
| -11% | -$316K | 0.21% | 137 |
|
|
2022
Q1 | $2.82M | Buy |
109,483
+96,274
| +729% | +$2.56M | 0.24% | 112 |
|
|
2021
Q4 | $410K | Buy |
+13,209
| New | +$372K | 0.03% | 584 |
|
|
2021
Q1 | – | Sell |
-28,563
| Closed | -$778K | – | 886 |
|
|
2020
Q4 | $778K | Sell |
28,563
-23,472
| -45% | -$548K | 0.05% | 375 |
|
|
2020
Q3 | $961K | Buy |
52,035
+35
| +0.1% | +$680 | 0.06% | 315 |
|
|
2020
Q2 | $1.06M | Buy |
52,000
+12,900
| +33% | +$205K | 0.07% | 275 |
|
|
2020
Q1 | $570K | Buy |
+39,100
| New | +$588K | 0.05% | 342 |
|
|
2019
Q3 | – | Sell |
-27,064
| Closed | -$544K | – | 484 |
|
|
2019
Q2 | $544K | Sell |
27,064
-36,969
| -58% | -$730K | 0.03% | 302 |
|
|
2019
Q1 | $1.45M | Sell |
64,033
-4,142
| -6% | -$91.5K | 0.08% | 228 |
|
|
2018
Q4 | $1.54M | Buy |
68,175
+2,123
| +3% | +$52.8K | 0.09% | 232 |
|
|
2018
Q3 | $1.9M | Buy |
66,052
+5,593
| +9% | +$160K | 0.08% | 244 |
|
|
2018
Q2 | $1.65M | Sell |
60,459
-36,427
| -38% | -$970K | 0.06% | 282 |
|
|
2018
Q1 | $2.17M | Sell |
96,886
-182
| -0.2% | -$4.33K | 0.07% | 264 |
|
|
2017
Q4 | $2.04M | Sell |
97,068
-33,391
| -26% | -$763K | 0.06% | 299 |
|
|
2017
Q3 | $3.25M | Sell |
130,459
-20,700
| -14% | -$456K | 0.11% | 223 |
|
|
2017
Q2 | $2.93M | Buy |
151,159
+115,503
| +324% | +$2.09M | 0.12% | 216 |
|
|
2017
Q1 | $658K | Buy |
+35,656
| New | +$697K | 0.03% | 356 |
|
|
2015
Q3 | – | Sell |
-30,240
| Closed | -$1M | – | 1576 |
|
|
2015
Q2 | $1M | Sell |
30,240
-9,519
| -24% | -$261K | 0.03% | 746 |
|
|
2015
Q1 | $953K | Buy |
+39,759
| New | +$606K | 0.02% | 805 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
PDT Partners's TVTX Position: Q1 2026 in Review
PDT Partners reduced its Travere Therapeutics (TVTX) stake by 60% in Q1 2026, selling an estimated $2.68M and leaving 58,957 shares worth $1.75M. The position accounts for 0.1% of the portfolio, ranked #262.
PDT Partners first reported a position in TVTX in Q1 2015 and has held it in 31 quarters since. The position peaked at $6.73M in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- PDT Partners held 58,957 shares of Travere Therapeutics worth $1.75M as of Q1 2026.
- PDT Partners sold 89,764 Travere Therapeutics shares in Q1 2026, an estimated $2.68M.
- Travere Therapeutics made up 0.1% of PDT Partners's portfolio in Q1 2026, its #262 holding.
- PDT Partners first reported a position in Travere Therapeutics in Q1 2015 and has held it in 31 quarters since.
- PDT Partners's Travere Therapeutics position peaked at $6.73M in Q3 2025.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.